Hospital purchasing decisions for medical devices are multi-stakeholder processes that involve clinicians, administrators, finance, supply chain, quality, IT, and formal committee structures. For anyone asking who makes purchasing decisions at hospitals, the answer is no longer one person but a coordinated group of hospital leaders. A systematic review published in BMJ Open found that the two most prominent elements across hospital purchasing processes were the roles of various stakeholders involved and the approaches to balancing technical, financial, and clinical requirements. The research also found that clinical evidence and cost-effectiveness consistently ranked as more important than personal preference, regardless of the stakeholder’s role.
That last point is worth sitting with. Even the people on the committee who are clinicians are evaluating your device through a value-based lens. The days of a single physician driving a purchase based on preference alone are effectively over for any device with a meaningful budget impact. This is why understanding hospital purchasing decision makers medical device companies must engage is now central to growth.
NAMSA’s 2025 Hospital Purchasing Behavior report, based on surveys of 100 procurement decision-makers across U.S. and European hospitals, confirmed that procurement processes are slowing down due to increased stakeholder involvement, tightening budgets, and demands for robust clinical evidence. One Chief of Operations surveyed in the report said they are taking extra time to assess risks and ensure they are making the best possible choice. This is the modern hospital buying process medical device companies need to prepare for before entering a sales conversation.
Here are the seven people who matter, what each one evaluates, and how to prepare for all of them. Together, they represent the core medical device hospital sales stakeholders and medtech hospital adoption stakeholders that determine whether a product moves from clinical interest to approved adoption.
1. The Physician Champion
The physician champion is the clinician, usually a surgeon, interventionalist, or department-level specialist, who has used or evaluated your product and believes it delivers superior clinical outcomes. This person is the engine of the entire hospital adoption process. Without a committed physician champion, most hospital purchasing processes never get started. This is the foundation of physician champion medical device sales.
What they care about is clinical performance, patient outcomes, safety, and whether the device fits into their procedural workflow without adding friction. They are the closest to the patient and the most focused on whether the technology genuinely improves care.
Here is the part most medtech companies miss. The physician champion’s enthusiasm gets you to the table. It does not get you through it. In the current hospital environment, a physician preference alone is no longer enough to justify a purchase. According to Definitive Healthcare, physician-preferred items account for 40 to 60 percent of a hospital’s total supply costs. These physician preference items are under intense scrutiny, and the champion’s advocacy must be backed by the kind of evidence and economic data that the rest of the committee requires.
Your job is to make the champion’s advocacy as easy and effective as possible. That means equipping them with clinical evidence summaries they can reference quickly, financial models that anticipate the questions other committee members will ask, and answers to the most common objections. If your champion cannot answer a question in the committee room, the item gets deferred to the next meeting cycle. And many value analysis committees only meet monthly or quarterly.
The strongest submissions have more than one champion. When interest comes from multiple physicians or across multiple departments, it signals broader adoption potential and makes the request look like an institutional need rather than a single physician’s preference.
2. The Department Head
The department head, whether that is a chief of surgery, a department chair, a service line director, or a nursing director, sits one level above the physician champion in the clinical hierarchy. They have budget responsibility, staffing oversight, and a view of how a new device fits into the broader strategic direction of their department or service line.
What they care about is operational impact, staffing implications, whether the device aligns with the department’s clinical priorities, and whether the business case justifies pulling budget or headcount toward implementation. They also care about disruption. A new device that requires significant retraining or changes to established workflows raises a red flag, because the department head is the one who will deal with the fallout if adoption goes poorly.
The department head is often the person who formally submits the product request to the value analysis committee. In many institutions, the vendor cannot submit directly. The request must come from an internal clinical leader. This means the department head needs to believe the case is strong enough to put their name on it.
For medtech companies, the department head is where the clinical story meets the operational and financial story. Your champion might say the device is better. The department head wants to know better by how much, at what cost, with what level of disruption, and whether the department’s current budget can absorb it. If the answer is “this requires a capital budget request,” the timeline just extended by one to two budget cycles. This is where medical device commercial strategy has to connect clinical value with department-level business impact.
3. The Supply Chain and Procurement Leader
The supply chain leader, sometimes called the director of materials management or VP of supply chain, evaluates every new product through the lens of sourcing efficiency, vendor management, and cost control. This is one of the most influential and most underestimated stakeholders in the buying process. It is also one of the clearest examples of hospital supply chain procurement medical device decision-making.
What they care about is pricing relative to existing contracts, GPO alignment, vendor consolidation risk, supply reliability, and total acquisition cost. According to the Healthcare Supply Chain Association, approximately 97 percent of U.S. hospitals are affiliated with a group purchasing organization. That means the supply chain leader is almost always evaluating your product against existing GPO contract pricing. If your device is off-contract or from a vendor with no GPO relationship, you need a compelling reason for the hospital to go outside the established purchasing framework.
The supply chain leader also thinks about operational continuity. They want to know about product availability, lead times, backup options if supply is disrupted, and whether your company has the distribution infrastructure to deliver reliably. Vizient’s Summer 2025 Spend Management Outlook projected a 2.41 percent increase in medical supply chain costs for 2026, and the AHA reported that total hospital spending on supplies increased 9.9 percent through 2025. In that cost environment, the supply chain leader’s default stance toward any new product is skepticism. You need to earn their confidence with data, competitive pricing, and clear procurement logistics.
One thing most medtech CEOs do not realize is that the supply chain leader often has veto power in practice, even if they do not have it formally. If supply chain raises a serious concern about vendor risk, pricing, or contract structure, the rest of the committee typically defers to their judgment. Address their concerns proactively and you remove one of the most common sources of silent deal death.
4. The CFO or Finance Representative
The hospital CFO or their designated finance representative evaluates every new device purchase through a financial lens. In the current environment, that lens is sharper than it has ever been. This is the stakeholder behind hospital CFO medical device purchasing evaluation.
What they care about is total cost of ownership, reimbursement impact, budget cycle alignment, projected return on investment, and whether the expense is budgeted or unbudgeted. They are thinking about the income statement, cash flow, and how this purchase affects the institution’s financial performance over one, three, and five years. In this context, total cost of ownership means the full financial impact of the device, including acquisition cost, implementation cost, training, service, maintenance, reimbursement effect, and long-term operating burden.
Strata Decision Technology reported that the median year-to-date operating margin for U.S. health systems was negative 0.3 percent in February 2026. Kaufman Hall’s February 2026 National Hospital Flash Report noted that expenses rose across the board through 2025, bad debt increased, and an eroding payer mix shifted more revenue toward government programs. A 2026 SmartSense survey of 150 U.S. hospital CFOs found that the most crucial factors for technology investment approval were compliance alignment (cited by 45 percent), quantified ROI within a defined timeframe (42 percent), and total cost of ownership (39 percent).
For medtech companies, the finance representative is where the economic case lives or dies. They want to see per-case cost comparisons against the current standard. They want to understand reimbursement clearly, not vaguely. And they want conservative financial projections, not optimistic marketing estimates. A financial model with three scenarios (conservative, moderate, and optimistic) that the finance team can pressure-test will carry far more weight than a slide deck with a single ROI projection.
One critical nuance: the finance representative is almost always comparing your device against the status quo, which is continuing with whatever the hospital currently uses. Your financial case needs to address the cost and risk of doing nothing, not just the cost of adopting your product.
5. The Value Analysis Committee Chair
The value analysis committee chair is the person who manages the committee’s agenda, sets submission requirements, and facilitates the evaluation process. This is typically a supply chain director, a clinical director, or a senior administrator who has been designated to run the committee.
A value analysis committee is the formal multidisciplinary body within a hospital or health system responsible for evaluating whether a new product, device, or technology should be approved for clinical use. The committee typically meets monthly or quarterly and reviews submissions against criteria that span clinical evidence, economic impact, operational fit, and strategic alignment. In practical terms, the chair coordinates the work of hospital value analysis committee members.
What the chair cares about is process integrity. They want complete, well-organized submissions that follow the committee’s format. They want evidence that has been vetted, financial projections that are realistic, and a clear rationale for why this product should be evaluated at all. The chair is also managing competing priorities. Your submission is one of several on the agenda, and incomplete packages get deferred.
Research published in Value in Health found that VAC adoption in U.S. hospitals expanded significantly, with nearly half of surveyed hospitals having introduced their committee within the preceding five years at the time of the study. As these committees mature, their processes become more formalized and their evidence requirements increase. Early-stage medtech companies often underestimate how structured the VAC process has become. Submitting a product brochure and a few testimonials does not meet the bar anymore.
Build a relationship with the committee chair or their office before the submission goes in. Understand the meeting schedule, the required format, the evidence standards, and the common reasons products get deferred. Every institution is slightly different, and tailoring your approach to each hospital’s process can prevent unnecessary delays.
6. The IT and Clinical Engineering Leader
The IT leader, sometimes a CIO, a director of clinical engineering, or a health IT security officer, evaluates any product that touches the hospital’s technology infrastructure. This includes devices that integrate with the electronic health record, generate data, require network connectivity, or involve any form of software. This is the core of hospital IT clinical engineering device evaluation.
What they care about is interoperability, cybersecurity, data standards compliance (HL7/FHIR), network security, and whether the device introduces IT support burden. In 2026, cybersecurity has become a top-tier concern. Becker’s Hospital Review reported that health systems are taking a more disciplined approach to technology investments in 2026, driven by pressure to reduce complexity and ensure spending translates into enterprise-wide value.
For many medtech products, especially anything involving digital therapeutics, connected devices, surgical robotics, or remote monitoring, the IT evaluation can be as time-consuming as the clinical evaluation. If your device requires IT resources for implementation, integration testing, or ongoing support, the IT leader needs to know exactly what is involved. Underestimating the IT integration requirement is one of the fastest ways to stall a deal that was otherwise moving forward.
Clinical engineering also plays a role that is often overlooked. A systematic review of hospital purchasing processes published in BMJ Open specifically highlighted the clinical engineering team as a genuine stakeholder in final purchasing decisions, particularly for capital equipment and devices that require ongoing maintenance, calibration, or technical support. In this article, clinical engineering refers to the hospital team responsible for evaluating, maintaining, integrating, and supporting medical equipment across its life cycle.
Prepare IT-specific documentation early. That means architecture diagrams, data flow documentation, cybersecurity certifications, compatibility testing results, and a clear description of what IT resources will be required for implementation and ongoing operations. If you can show that your device reduces IT burden rather than adding to it, that becomes a powerful selling point with this stakeholder.
7. The Compliance, Quality, and Risk Management Officer
The quality and compliance officer, sometimes a chief quality officer, a risk manager, or a regulatory affairs leader, evaluates your product through the lens of patient safety, regulatory compliance, and institutional risk. This is the stakeholder most focused on what could go wrong.
What they care about is FDA regulatory status, post-market surveillance data, adverse event history, recall history, alignment with the hospital’s quality and safety goals, and liability exposure. They want to know that your device has a clean regulatory file, that your company has a mature quality management system, and that you are monitoring real-world performance data.
This stakeholder also thinks about how adoption affects the hospital’s accreditation status, compliance with CMS conditions of participation, and exposure to medical malpractice risk. If your device has any history of FDA warning letters, product recalls, or significant adverse event reports, this person will find it. Be proactive about disclosing and contextualizing any regulatory issues rather than hoping they go unnoticed.
In the current environment, quality and compliance have taken on additional financial significance. The AHA’s 2026 Costs of Caring report documented rising bad debt, increasing denial rates, and growing administrative complexity. Risk management is directly tied to financial performance, and the compliance officer is thinking about both patient safety and the institution’s financial exposure when a new product is introduced.
For medtech companies, this means your submission should include complete FDA clearance or approval documentation, a summary of any post-market surveillance findings, a description of your quality management system, and references to any clinical safety databases or registries where your device’s performance is being tracked.
Why Most Medtech Companies Only Sell to Two of the Seven
The pattern is remarkably consistent. Most medtech companies, especially those between $3M and $30M in revenue, have built their commercial materials and sales process around two stakeholders: the physician champion and, to a lesser extent, the department head. They have a strong clinical story. They may even have a compelling product demo. But they have almost nothing prepared for the other five people in the buying process.
That gap is where deals die. The physician says yes. Supply chain raises a concern about GPO alignment. Finance asks for total cost of ownership data that does not exist. The VAC chair defers because the submission is incomplete. IT flags a cybersecurity question no one can answer. And the deal quietly stalls for months, sometimes permanently.
NAMSA’s 2025 report found that 58 percent of hospitals stay loyal to their current vendor on average, and switches are primarily driven by new product offerings and enhanced technology. That means you need to give the full buying committee a reason to switch. One physician’s preference, no matter how strong, rarely meets that bar alone.
Building the right content, evidence, and tools for each of the seven stakeholders is a marketing and commercial strategy problem, and it needs to be solved before the sales team ever walks into the first meeting. This is the essence of medtech multi-stakeholder selling and a stronger medical device commercial strategy. If you want a full framework for how to map these stakeholders, build the evidence package for each one, and design a commercial process around how hospitals actually buy, I put together The 2026 Hospital Adoption Playbook for Medical Device Companies. It covers the entire process from initial clinical interest through system-wide adoption.
Frequently Asked Question
Who is involved in hospital purchasing decisions for medical devices?
Hospital purchasing decisions for medical devices typically involve seven key stakeholders: the physician champion, the department head, the supply chain and procurement leader, the CFO or finance representative, the value analysis committee chair, the IT and clinical engineering leader, and the compliance, quality, and risk management officer. Each stakeholder evaluates the product through a different lens, from clinical efficacy to financial impact to operational fit and regulatory compliance. A systematic review published in BMJ Open confirmed that bringing together a multidisciplinary team is consistently identified as the key feature of successful purchasing processes.
What is a physician champion in medical device sales?
A physician champion is the clinician, typically a surgeon or specialist, who has used or evaluated a medical device and advocates for its adoption within the hospital. The physician champion usually submits the formal request to the value analysis committee and serves as the internal advocate throughout the evaluation process. While essential, physician advocacy alone is no longer sufficient to drive a purchase. According to Definitive Healthcare, physician-preferred items represent 40 to 60 percent of hospital supply costs, and that spending is under increased institutional scrutiny.
What role does the hospital CFO play in medical device purchases?
The hospital CFO or finance representative evaluates medical device purchases through a financial lens that includes total cost of ownership, reimbursement impact, budget cycle alignment, and projected return on investment. A 2026 SmartSense survey of 150 U.S. hospital CFOs found that the top factors for technology investment approval were compliance alignment (45 percent), quantified ROI within a defined timeframe (42 percent), and total cost of ownership (39 percent). With median health system operating margins at negative 0.3 percent in early 2026 according to Strata Decision Technology, financial scrutiny on every purchasing decision has intensified significantly.
How does the supply chain department influence hospital device purchases?
The supply chain department evaluates medical device purchases based on pricing competitiveness, GPO contract alignment, vendor consolidation risk, supply reliability, and total acquisition cost. According to the Healthcare Supply Chain Association, approximately 97 percent of U.S. hospitals are affiliated with a GPO, meaning most new products are evaluated against existing contract pricing. Supply chain leaders often have effective veto power over new product introductions, particularly when a device is off-contract or introduces vendor management complexity.
Why do medical device sales require multi-stakeholder engagement?
Medical device sales require multi-stakeholder engagement because hospital purchasing decisions are made by cross-functional committees, not individual buyers. NAMSA’s 2025 Hospital Purchasing Behavior report confirmed that procurement processes are slowing due to increased stakeholder involvement, tightening budgets, and demands for robust clinical evidence. A BMJ Open systematic review found that clinical evidence and cost-effectiveness ranked as more important than personal preference regardless of stakeholder role. Companies that only engage the physician champion leave five or more stakeholders unaddressed, which is the primary reason deals stall after initial clinical interest.
How does IT influence hospital medical device purchases?
The IT and clinical engineering team evaluates medical devices for interoperability, cybersecurity compliance, data standards (HL7/FHIR), network security, and IT support burden. In 2026, health systems are applying heightened scrutiny to technology investments, demanding that spending translate into enterprise-wide value rather than adding complexity. For connected devices, digital therapeutics, or any product requiring EHR integration, the IT evaluation can be as time-consuming as the clinical evaluation and can independently stall a deal if integration concerns are unresolved.
What does the value analysis committee chair do in a medical device purchase?
The value analysis committee chair manages the committee’s agenda, sets submission requirements, and facilitates the evaluation process for new products. The chair ensures submissions meet the committee’s evidence standards and procedural requirements. Incomplete or poorly organized submissions are typically deferred to a future meeting cycle. Since many VACs meet monthly or quarterly, a single deferral can add 30 to 90 days to the purchasing timeline. Building a relationship with the committee chair and understanding the institution’s specific submission format is critical for efficient progression through the evaluation process.
How should medtech companies prepare for the hospital buying process?
Medtech companies should build distinct content, evidence, and tools for each of the seven stakeholders in the hospital buying process. This means clinical evidence dossiers for the physician champion, operational impact assessments for the department head, GPO pricing comparisons for supply chain, total cost of ownership models for finance, a complete submission package for the VAC chair, IT integration documentation for clinical engineering, and regulatory compliance summaries for quality and risk management. Companies between $3M and $30M in revenue most commonly fail because they only prepare materials for the clinician, leaving five or more stakeholders unaddressed.
If your deals keep stalling after the clinician says yes, the problem is almost certainly with the other six people in the buying process. I work with high-growth medtech companies as a fractional CMO, helping leadership teams build the commercial infrastructure to address every stakeholder in the hospital buying process systematically.
To your success,
Sunny
